Recon: FDA places Gilead’s blood cancer drug trials on hold; FDA found quality control lapses at Catalent’s Bloomington plant
ReconJason Scott
Biologics/ biosimilars/ vaccinesEuropeGlobalMedical DevicesNorth AmericaPharmaceuticalsRegulatory Intelligence/PolicyUnited States